Ocera Therapeutics Inc(NASDAQ:OCRX) announced the earnings results for Fiscal Year 2016 and Q2. The results came in during After-hours on Aug 3, 2016. Company reported revenue of $26.00K. Analysts estimated a revenue of $20.00K. Earnings per share were $-0.33. Analysts had estimated an EPS of $-0.35.
Ocera Therapeutics Inc (OCRX) remained unchanged at the close of Friday session. Even as the volume increased to 21,305 ,the shares failed to make any impression and ended at 0 points or 0.00% at $2.5. The trading session commenced at $2.3999 and the stock hit a high of $2.5 and touched $2.38 at the lower end. Considering that the stock pared all of the losses, it can be said as a positive sign. The share price has a 52-week high of $4.57 and the 52-week low is $1.759. The company has a market cap of $55 M and has approximately 2,18,51,488 outstanding shares.
Several Insider Transactions has been reported to the SEC. On Mar 7, 2016, Linda S Grais (CEO) purchased 3,000 shares at $3.19 per share price.Also, On Jan 19, 2016, Michael Byrnes (CFO) purchased 3,500 shares at $2.07 per share price.On Jan 19, 2016, Gaurav Aggarwal (Chief Business Officer) purchased 10,000 shares at $2.15 per share price, according to the Form-4 filing with the securities and exchange commission.
Ocera Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on acute and chronic orphan liver diseases. The Company is focused on the development and commercialization of a clinical candidate OCR-002 for the treatment of hepatic encephalopathy (HE). OCR-002 is a molecule ornithine phenylacetate which functions as an ammonia scavenger. In pre-clinical studies OCR-002 reduced arterial ammonia in an animal model of chronic liver disease and reduced arterial ammonia brain ammonia and intracranial pressure in a second animal model of acute liver failure. The Company has completed a Phase I pharmacokinetic and safety clinical trial of the intravenous form of OCR-002. A Phase IIa investigator-sponsored study in Spain tested OCR-002 in patients with upper gastrointestinal bleeding associated with liver cirrhosis. The Company is conducting a randomized placebo-controlled double blind Phase IIb clinical trial of OCR-002.